dyslipidemia Flashcards
statins MOA and when to take
inhibition of HMG-CoA reductase -> no conversion of HMG-CoA to mevalonate (RLS in cholesterol biosynthesis)
take in the evening; cholesterol synthesis is max from 12 - 2 AM
statin metabolism
metabolized by CYP3A4
AE’s increased with concomitant use of CYP3A4 inhibitors, macrolides, azole antifungles, amiodarone, HN protease inhibitors, and gemfibrozil
statin AE
increase in serum transaminases, myalgia, weakness, rhabdomyolysis
statin contraindications
acute liver disease, persistent unexplained increased serum transaminases, pregnancy
statin monitoring
LFTs (baselines and as clinically indicated thereafter); discontinue if >3x ULN CK levels (baseline and if sxs appear); discontinue if >10x ULN
statin avoiders
grapefruit juice (interferes with CYP3A4) red yeast rice (contains statin active ingredient)
bile acid-binding resins agents
holesyramine, colestipol, colesevelam
BARs MOA
increase LDL catabolism and decrease cholesterol absorption
bind bile acids to prevent reabsorption -> increase cholesterol-using bile synthesis -> increase LDL uptake and clearance
BARs ADME
powder form mixed with water
not systemically absorbed
BARs AE’s
GI (dyspepsia, bloating, abdominal discomfort)
hepatic (hypertriglyceridemia, increased serum transaminases)
pancreatitis
BAR absorption interactions
levothyroxine, warfarin, verapamil, phenytoin (administer 1 hr before or 3-4 after BAR)
fibric acid derivatives agents
gemfibrozil, fenofibrate, fenofibric acid
fibric acid derivatives MOA
increase VLDL clearance and decrease synthesis
activate nuclear transcription factor perioxisome proliferator activated receptor alpha (PPAR-alpha) on hepatocytes -> regulate lipid and glucose metabolism genes -> inhibit lipolysis and decrease hepatic fatty acid uptake
fibric acid derivatives AE’s
increased serum transaminases, myalgia / weakness
fibric acid derivatives contraindications
significant hepatic or renal dysfunction, primary biliary cirrhosis, pre-existing gall bladder disease